Lilly

Eli Lilly is undertaking a strategic transformation that will result in the formation of new business units. The Indianapolis company’s Bio-Medicines unit will split into two separate businesses, with one focused on neuroscience and the other concentrated on immunology.

Activist investor Elliott Management continues to push for a change in leadership at GlaxoSmithKline ahead of the planned 2022 split of the company.